Defibrillation Thresholds in Hypertrophic Cardiomyopathy

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY(2009)

Cited 30|Views6
No score
Abstract
Background: Defibrillation threshold (DFT) testing is performed in part to ensure an adequate safety margin for the termination of spontaneous ventricular arrhythmias. Left ventricular mass is a predictor of high DFTs, so patients with hypertrophic cardiomyopathy (HCM) are often considered to be at risk for increased defibrillation energy requirements. However, there are little prospective data addressing this issue. Objective: To assess DFTs in patients with HCM and evaluate the clinical predictors of elevated DFTs. Methods: Eighty-nine consecutive patients with HCM and 600 control patients with ischemic or nonischemic cardiomyopathy underwent a uniform modified step-down DFT testing protocol. DFT was compared between the control and HCM populations. Predictors of elevated DFT were evaluated in the HCM group. Results: There was no difference in DFT between HCM and control groups (10.4 +/- 5.8 J vs 11.2 +/- 5.6 J, respectively). Among patients with HCM, clinical parameters such as left ventricular ejection fraction, interventricular septal thickness, left ventricular mass, and QRS duration were not predictive of an elevated DFT. Only 3 patients (3.4%) with HCM had a DFT > 20 J. Conclusion: Patients with HCM do not have elevated DFTs as compared to more typical populations undergoing implantable cardioverter-defibrillator implant; high-energy devices or complex lead systems are not needed routinely in this population. (J Cardiovasc Electrophysiol, Vol. 22, pp. 569-572 May 2011).
More
Translated text
Key words
defibrillation threshold,hypertrophic cardiomyopathy,implantable cardioverter defibrillator
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined